TRCT
TRAW icon

Tower Research Capital (TRC)’s Traws Pharma TRAW Stock Holding History

Tower Research Capital (TRC)’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.34K Buy
5,142
+1,178
+30% +$1.62K ﹤0.01% 4400
2026
Q1 		$7.25K Buy
+3,964
New +$7.45K ﹤0.01% 4013
2025
Q3 		– Sell
-706
Closed -$1.04K – 5696
2025
Q2 		$1.04K Sell
706
-2,555
-78% -$4.07K ﹤0.01% 4886
2025
Q1 		$7.5K Buy
+3,261
New +$17K ﹤0.01% 3947
2024
Q4 		– Sell
-379
Closed -$2.23K – 6072
2024
Q3 		$2.23K Buy
379
+239
+171% +$2.17K ﹤0.01% 5026
2024
Q2 		$1.57K Buy
140
+1
+0.7% +$16 ﹤0.01% 5134
2024
Q1 		$3.52K Sell
139
-3
-2% -$58 ﹤0.01% 4848
2023
Q4 		$2.65K Sell
142
-9
-6% -$153 ﹤0.01% 5185
2023
Q3 		$2.69K Buy
151
+9
+6% +$205 ﹤0.01% 5118
2023
Q2 		$4.19K Sell
142
-68
-32% -$1.83K ﹤0.01% 4977
2023
Q1 		$4K Buy
+210
New +$4.54K ﹤0.01% 5119
2022
Q2 		– Sell
-59
Closed -$3K – 6597
2022
Q1 		$3K Sell
59
-65
-52% -$3.01K ﹤0.01% 5436
2021
Q4 		$8K Sell
124
-110
-47% -$8.85K ﹤0.01% 4836
2021
Q3 		$22K Buy
234
+232
+11,600% +$29.9K ﹤0.01% 3649
2021
Q2 		$0 Sell
2
-127
-98% -$28.7K ﹤0.01% 5902
2021
Q1 		$48K Sell
129
-164
-56% -$61.9K ﹤0.01% 3165
2020
Q4 		$51K Buy
+293
New +$34K ﹤0.01% 3111
2019
Q4 		– Sell
-1
Closed – – 4497
2019
Q3 		$0 Buy
+1
New +$861 ﹤0.01% 4579
2016
Q4 		– Hold
0
– -$1K – 4481
2016
Q3 		– Hold
0
– – – 3388
2016
Q1 		– Hold
0
– -$1K – 5059
2015
Q4 		– Hold
0
– – – 4186
2015
Q3 		– Hold
0
– – – 4888
2015
Q2 		– Hold
0
– – – 3806
2015
Q1 		– Hold
0
– – – 5018
2014
Q4 		– Hold
0
– -$45K – 4779
2014
Q3 		– Hold
0
– – – 1623
2014
Q2 		– Hold
0
– – – 3777
2014
Q1 		– Hold
0
– – – 5014
2013
Q4 		– Hold
0
– – – 2461
2013
Q3 		– Hold
0
– – – 587

Other funds holding TRAW

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Tower Research Capital (TRC)'s TRAW Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Traws Pharma (TRAW) stake by 30% in Q2 2026, buying an estimated $1.62K and bringing the position to 5,142 shares worth $4.34K. The position accounts for ﹤0.01% of the portfolio, ranked #4400.

Tower Research Capital (TRC) first reported a position in TRAW in Q3 2019 and has held it in 18 quarters since. The position peaked at $51K in Q4 2020. 20 funds tracked by Wall St. Rank hold TRAW as of Q2 2026.

  • Tower Research Capital (TRC) held 5,142 shares of Traws Pharma worth $4.34K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,178 Traws Pharma shares in Q2 2026, an estimated $1.62K.
  • Traws Pharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4400 holding.
  • Tower Research Capital (TRC) first reported a position in Traws Pharma in Q3 2019 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s Traws Pharma position peaked at $51K in Q4 2020.
  • 20 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.